Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1975806
Reference Type
Journal Article
Title
EGFR and KRAS mutations in patients with adenocarcinoma of the lung
Author(s)
Jang, TW; Oak, CH; Chang, HK; Suo, SJ; Jung, MH
Year
2009
Is Peer Reviewed?
0
Journal
Daihan Naigwa Haghoi Jabji/Korean Journal of Internal Medicine
ISSN:
0494-4712
Volume
24
Issue
1
Page Numbers
48-54
Language
English
PMID
19270482
DOI
10.3904/kjim.2009.24.1.43
Abstract
BACKGROUND/AIMS:
Mutations of the epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) are important in the pathogenesis of lung cancer, and recent reports have revealed racial and geographical differences in mutation expression.
METHODS:
This study was conducted to investigate the prevalence of EGFR and KRAS mutations and their correlation with clinical variables in Korean patients with adenocarcinoma of the lung. Formalin-fixed adenocarcinoma specimens from 104 randomly selected patients diagnosed at Kosin University Gospel Hospital from October 1996 to January 2005 were used for the study.
RESULTS:
We found a high prevalence of EGFR mutations and a low prevalence of KRAS mutations. EGFR mutations were present in 24% (25 of 104) of the samples: one mutation in exon 18, 13 in exon 19, one in exon 20, and 10 in exon 21. The presence of an EGFR mutation was not associated with gender, smoking history, histological grade, age, bronchioalveolar components, or cancer stage in patients with adenocarcinoma of the lung.
CONCLUSIONS:
Mutations of KRAS were present in 9.6% (9 of 94) of the samples: eight in codon 12 and one in codon 13. EGFR mutations were never found in tumors with KRAS mutations, suggesting a mutually exclusive relationship.
Keywords
Adenocarcinoma/ genetics/metabolism/mortality; DNA, Neoplasm/ genetics; Gene Expression Regulation, Neoplastic; Korea/epidemiology; Lung Neoplasms/ genetics/metabolism/mortality; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins/biosynthesis/ genetics; Receptor, Epidermal Growth Factor/biosynthesis/ genetics; Retrospective Studies; Survival Rate; ras Proteins/biosynthesis/ genetics
Tags
IRIS
•
Formaldehyde
Reproductive and Developmental Effects
Screened
Title/abstract
Methodology/therapeutics
Retroactive RIS import
2015
FA DevRepro 072115
Methodology/Therapeutics-Population Criteria
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity